NCT05095896 is a clinical trial of ITP patients in Immune Thrombocytopenia, sponsored by Ming Hou.

Who is sponsoring NCT05095896?

NCT05095896 is sponsored by Ming Hou.

What drugs are being tested in NCT05095896?

Interventions in NCT05095896: ITP patients.

What condition does NCT05095896 study?

NCT05095896 studies Immune Thrombocytopenia.

Is NCT05095896 still recruiting?

NCT05095896 is currently completed. Last updated 27 October 2021.

Last reviewed 2021-10-27 · How we verify

NCT05095896

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Serum Lipid Profiles in ITP: a Retrospective Study

Completed Last updated 27 October 2021

What this trial tests

trial testing ITP patients in Immune Thrombocytopenia in 457 participants. Completed in 1 December 2020.

Timeline

1 January 2018

Primary endpoint
1 December 2020

1 December 2020

Quick facts

Lead sponsor	Ming Hou
Status	Completed
Study type	OBSERVATIONAL
Enrollment	457
Start date	1 January 2018
Primary completion	1 December 2020
Estimated completion	1 December 2020
Sites	1 location across China

Drugs / interventions tested

ITP patients

Conditions studied

Immune Thrombocytopenia — all drugs for Immune Thrombocytopenia →

Sponsor

Ming Hou — full company profile →

Who can join

Adults 18 to 75, any sex, with Immune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project was retrospectively undertaking by Qilu Hospital of Shandong University in China. In order to investigate the correlations between platelet indices, serum lipids and bleeding symptoms in ITP.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The serum lipid profiles in immune thrombocytopenia: Mendelian randomization analysis and a retrospective study.
Xu P, Han S, Hou M, Zhao Y, et al · · 2023 · cited 5× · PMID 37833799 · DOI 10.1186/s12959-023-00551-x
The serum lipid profiles in immune thrombocytopenia: mendelian randomization analysis and a retrospective study
Xu P, Zhao Y, Hou M, Xu M. · · 2023 · DOI 10.21203/rs.3.rs-2869234/v1

Verify or expand the search:

Other recruiting trials for Immune Thrombocytopenia

Currently open trials in the same condition.

NCT07104565 — Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Diso · Phase 2 · recruiting
NCT07007962 — Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed · Phase 3 · recruiting
NCT07216079 — Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan · Phase 3 · active not recruiting
NCT06776510 — A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia · Phase 1, PHASE2 · recruiting
NCT06715215 — Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05095896 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ming Hou
Last refreshed: 27 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05095896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing